# US 2021/0230170 A1 · Kras g12c inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230170 A1
- Document ID: US20210230170A1
- Status: Published application
- Kind: A1
- Application number: 17/272,276
- Filed: 2019-08-29
- Published: 2021-07-29
- Earliest claimed: 2018-08-31
- Assignees: Mirati Therapeutics, Inc.; Array BioPharma Inc.
- Applicants: Mirati Therapeutics, Inc.; Array BioPharma, Inc.
- Inventors: Matthew Arnold Marx; James F. Blake; Jay Bradford Fell; John P. Fischer; Macedonio J. Mejia
- Web page: https://patentgrep.com/patent/US20210230170A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof:
wherein:
X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R8;
Y is a bond, O, S or NR5;
R1 is —C(O)C(RA)C(RB)p or —SO2C(RA)C(RB)p;
R2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, —Z—NR5R10, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R9;
each Z is C1-C4 alkylene;
each R3 is independently C1-C3 alkyl, halogen or —OR5;
L is a bond, —C(O)—, or C1-C3 alkylene;
R4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R6, R7 or R8;
each R5 is independently hydrogen or C1-C3 alkyl;
R6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R7;
each R7 is independently halogen, hydroxyl, C1-C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;
R8 is oxo, C1-C3 alkyl, C2-C4 alkynyl, heteroalkyl, cyano, —C(O)OR5, —C(O)N(R5)2, —N(R5)2, wherein the C1-C3 alkyl may be optionally substituted with cyano, halogen, —OR5, —N(R5)2, or heteroaryl;
each R9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1-C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1-C6 alkyl may be optionally substituted with cycloalkyl;
each R10 is independently hydrogen, acyl, C1-C3 alkyl, heteroalkyl or hydroxyalkyl;
R11 is haloalkyl;
RA is absent, hydrogen, deuterium, cyano, halogen, C1-C-3 alkyl, haloalkyl, heteroalkyl, —C(O)N(R5)2, or hydroxyalkyl;
each RB is independently hydrogen, deuterium, cyano, C1-C3 alkyl, hydroxyalkyl, heteroalkyl, C1-C3 alkoxy, halogen, haloalkyl, —ZNR5R11, —C(O)N(R5)2, —NHC(O)C1-C3 alkyl, —CH2NHC(O)C1-C3 alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1-C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R7;
when is a triple bond then RA is absent, RB is present and p equals one,
or when is a double bond then RA is present, RB is present and p equals two, or RA, RB and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl optionally substituted with one or more R7;
m is 0, 1, 2 or 3; and
p is one or two.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1—X is:
wherein the piperazinyl ring is optionally substituted with R8.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is —C(O)C(RA)C(RB)p.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The compound of claim 3, wherein is a double bond and RA is hydrogen, p is two and at least one RB is independently hydrogen, deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, —ZNR5R11, —C(O)N(R5)2, —NHC(O)C1-C3 alkyl or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or C1-C3 alkyl.

### Claim at position 6

6-23. (canceled)

### Claim 24 (depends on 5)

The compound of claim 5, wherein is a double bond and p is two, each RB is hydrogen, and RA is deuterium, cyano, halogen, haloalkyl, heteroalkyl, —C(O)N(R5)2, or hydroxyalkyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein RA is halogen.

### Claim at position 9

26-32. (canceled)

### Claim 33 (depends on 2)

The compound of claim 2, wherein is a double bond and p is two, one RB is hydrogen, the second RB is dialkylaminylalkyl, and RA is halogen.

### Claim at position 11

34-35. (canceled)

### Claim 36 (depends on 2)

The compound according to claim 2, wherein Y is O.

### Claim 37 (depends on 2)

The compound according to claim 2, wherein R2 is selected from the group consisting of hydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, —ZNR5R10, heterocyclyl and heterocyclylalkyl, wherein each of the Z, heterocyclyl or heterocyclylalkyl are independently optionally substituted with R9.

### Claim 38 (depends on 37)

The compound of claim 37, wherein R2 is heterocyclylalkyl optionally substituted with one or more R9.

### Claim 39 (depends on 38)

The compound of claim 38, wherein the heterocyclyl of the heterocyclylalkyl is independently azetidinyl, methylazetidinyl, difluoroazetidinyl, tetrahydropyran, pyrrolidinyl, methylpyrrolidinyl, diemethylpyrrolidinyl, isopropylpyrrolidinyl, cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, fluoropyrrolidinyl, difluoropyrrolidinyl, (N-methyl)fluoropyrrolidinyl, (N-methyl)difluoropyrrolidinyl, methoxyethylpyrrolidinyl, (N-methyl)methoxypyrrolidinyl, piperazinyl, dimethylaminylpyrrolidinyl, morpholinyl, methylmorpholinyl, 1,4-oxazepanyl, piperdinyl, methylpiperidinyl acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl, dihalopiperdinyl, fluoropiperdinyl, difluoropiperdinyl, alkoxypiperdinyl, pyrrolidonyl, piperidinonyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, or azabicyclo[2.2.1]heptan-2-yl.

### Claim 40 (depends on 39)

The compound of claim 39, wherein the (N-methyl)difluoropyrrolidinyl is 3,3-difluoro-1-methylpyrrolidinyl.

### Claim 41 (depends on 39)

The compound of claim 39, wherein the heterocyclyl is N-methylpyrrolidinyl.

### Claim 42

(canceled)

### Claim 43 (depends on 2)

The compound according to claim 2, wherein R4 is aryl optionally substituted with one or more R7.

### Claim 44 (depends on 43)

The compound of claim 43, wherein the aryl is selected from the group consisting of phenyl and naphthyl optionally substituted with one or more R7.

### Claim 45 (depends on 44)

The compound of claim 44, wherein the phenyl and the naphthyl are each optionally substituted with one or more R7 selected from the group consisting of halogen, C1-C3 alkyl, haloalkyl, and hydroxyalkyl.

### Claim 46 (depends on 45)

The compound of claim 45, wherein R7 is selected from the group consisting of methyl, isopropyl, chloro, fluoro, and trifluoromethyl.

### Claim 47 (depends on 2)

The compound according to claim 2, wherein R4 is heteroaryl.

### Claim at position 24

48-89. (canceled)

### Claim 90 (depends on 2)

The compound according to claim 2, wherein R4 is aralkyl optionally substituted with one or more R7.

### Claim 91 (depends on 2)

The compound according to claim 2, wherein m is zero.

### Claim 92 (depends on 2)

The compound according to claim 2, wherein L is a bond.

### Claim 93 (depends on 2)

The compound according to claim 2, wherein R8 is heteroalkyl, C2-C4 alkynyl, or C1-C3alkyl optionally substituted with —OR5, cyano or heteroaryl.

### Claim 94 (depends on 93)

The compound of claim 93, wherein R8 is C1-C3 alkyl optionally substituted with cyano.

### Claim 95 (depends on 93)

The compound of claim 93, wherein R8 is cyanomethyl.

### Claim 96 (depends on 93)

The compound according to claim 93, wherein X is substituted with one R8.

### Claim 97 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 98 (depends on 1)

The compound of claim 1, wherein the compound is of Formula I-A:
wherein X is a piperazinyl ring optionally substituted with R8, where R1, R3, R4, R5, R8, R10, L and m are as defined in claim 1 and R11 is hydrogen, methyl or hydroxyalkyl.

### Claim 99 (depends on 98)

The compound of claim 98, wherein R1 is —C(O)C(RA)C(RB)p and is a double bond, each RB is hydrogen, and RA is deuterium, cyano, halogen, C1-C-3 alkyl, haloalkyl, heteroalkyl, —C(O)N(R5)2, or hydroxyalkyl.

### Claim 100 (depends on 1)

The compound of claim 1, wherein the compound is of Formula I-B:
where X is a piperazinyl ring optionally substituted with R8, and R1, R3, R4, R8, L and m are as defined in claim 1.

### Claim 101 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of Formula (I) according to claim 1, and a pharmaceutically acceptable excipient.

### Claim 102 (depends on 1)

A method for inhibiting KRas G12C activity in a cell, comprising contacting the cell in which inhibition of KRas G12C activity is desired with an effective amount of a compound of Formula (I) according to claim 1, pharmaceutically acceptable salts thereof or pharmaceutical compositions containing the compound of Formula (I), Formula I-A or Formula I-B, or pharmaceutically acceptable salt thereof.

### Claim 103 (depends on 1)

A method for treating cancer comprising administering to a patient having cancer a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof according to claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents.

### Claim 104 (depends on 103)

The method of claim 103, wherein the therapeutically effective amount of the compound is between about 0.01 to 100 mg/kg per day.

### Claim 105 (depends on 103)

The method of claim 103, wherein the cancer is selected from the group consisting of Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma.

### Claim 106 (depends on 105)

The method of claim 105, wherein the cancer wherein the cancer is a KRas G12C-associated cancer.

### Claim 107 (depends on 103)

The method of claim 103, wherein the cancer is non-small cell lung cancer.

### Claim 108 (depends on 1)

A method for treating cancer in a patient in need thereof, the method comprising (a) determining that the cancer is associated with a KRas G12C mutation (e.g., a KRas G12C-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, or a pharmaceutical composition thereof.
